Eli Lilly, a prominent US pharmaceutical company, has announced a significant reduction in its investment plan for a high-tech manufacturing plant in Alzey, Rhineland-Palatinate, Germany, slashing it from €2.3 billion ($2.67 billion) to €1.15 billion. This decision comes in response to newly proposed healthcare reforms by German Health Minister Nina Warken, which aim to reduce costs within the statutory health insurance system by imposing higher discounts and restrictive pricing agreements on pharmaceutical companies. CEO Dave Ricks criticized the reforms as a 'terrible signal to the industry,' warning that Germany risks falling behind in the European market. The investment cut will lead to a reduced operational capacity for the plant, which is still set to begin production in 2027, and a decrease in the anticipated workforce from 1,000 to 500 jobs. Additionally, the financial repercussions have prompted other companies, such as Boehringer Ingelheim, to cancel substantial investments, indicating a broader trend of capital flight from Germany's pharmaceutical sector.